Yoneda, Masato
Yokohama City University
13 papers on CoChatORCID 0000-0001-7815-549X
Most cited papers
- Verified
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 1,005
- Verified
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
Mózes, F. E., Lee, J. A., Selvaraj, E. A., Jayaswal, A. N. A., Trauner, M., Boursier, J., Fournier, C., Staufer, K., Stauber, R. E., Bugianesi, E., et al. (2022) · Gut
Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation
Cited by 556
- Verified
Hyperresponsivity to Low-Dose Endotoxin during Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-Mediated Signaling
Imajo, K., Fujita, K., Yoneda, M., Nozaki, Y., Ogawa, Y., Shinohara, Y., Kato, S., Mawatari, H., Shibata, W., Kitani, H., et al. (2012) · Cell Metabolism
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 341
- Verified
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH
Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., et al. (2007) · Journal of Gastroenterology
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 294
- Verified
Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease
Lin, H., Lee, H. W., Yip, T. C.-F., Tsochatzis, E., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M.-H., Hagström, H., Boursier, J., et al. (2024) · JAMA
Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation
Cited by 250
- Verified
Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis # †
Fujita, K., Nozaki, Y., Wada, K., Yoneda, M., Fujimoto, Y., Fujitake, M., Endo, H., Takahashi, H., Inamori, M., Kobayashi, N., et al. (2009) · Hepatology
Liver Disease Diagnosis and TreatmentLipid metabolism and disorders
Cited by 244
- Verified
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology
Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation
Cited by 214
- Verified
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
Nakajima, A., Eguchi, Y., Yoneda, M., Imajo, K., Tamaki, N., Suganami, H., Nojima, T., Tanigawa, R., Iizuka, M., Iida, Y., et al. (2021) · Alimentary Pharmacology & Therapeutics
Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors
Cited by 213
- Verified
Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2022) · Hepatology Communications
Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management
Cited by 153
- Verified · note
Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease
Imajo, K., Honda, Y., Kobayashi, T., Nagai, K., Ozaki, A., Iwaki, M., Kessoku, T., Ogawa, Y., Takahashi, H., Saigusa, Y., et al. (2022) · Clinical Gastroenterology and Hepatology
Liver Disease Diagnosis and TreatmentUltrasound Imaging and Elastography
Cited by 140
- Verified
Non‐alcoholic fatty liver disease comorbid with major depressive disorder: the pathological features and poor therapeutic efficacy
Tomeno, W., Kawashima, K., Yoneda, M., Saito, S., Ogawa, Y., Honda, Y., Kessoku, T., Imajo, K., Mawatari, H., Fujita, K., et al. (2015) · Journal of Gastroenterology and Hepatology
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 98
- Verified
The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease
Yoneda, M., Thomas, E., Sumida, Y., Eguchi, Y., & Schiff, E. R. (2014) · Hepatology
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 45
- Verified
Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2025) · Diabetes mellitus
Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management
Cited by 1
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free